Actively Recruiting
Evaluating Cannabidiol as an Add-On Treatment for First Episode Psychosis in a Randomized, Double-Blind Controlled Trial
Led by University of Oxford · Updated on 2026-10-08
250
Participants Needed
17
Research Sites
52 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating whether adding cannabidiol CBD to existing antipsychotic treatment improves response in people experiencing their first episode of psychosis who have not responded well or at all to their initial antipsychotic medication. This randomized, double-blind, placebo-controlled trial also aims to confirm the safety of CBD in this group. The study includes various clinical assessments and explores biomarkers to predict treatment outcomes, with optional blood, stool, and neuroimaging samples collected at certain sites. Participants will be randomly assigned to receive either CBD oral solution, dosed at 500mg twice daily or adjusted by weight if under 50 kg, or a matching placebo, both taken alongside their current antipsychotic medication for six weeks. The trial compares these two groups to assess the effect of CBD as an addition to standard treatment during this period. During the study, participants will undergo clinical assessments including symptom scales and functioning evaluations, with primary measurement focusing on changes in psychosis symptoms after six weeks. Biomarkers are assessed at baseline and six weeks to explore links to symptom improvement. Safety will be monitored throughout treatment and for 30 days afterward, with participants adherence and health status regularly evaluated. Total participation spans the treatment duration plus follow-up assessments extending up to 58 weeks for some measures.
CONDITIONS
Brief Title
Stratification and Treatment in Early Psychosis Study - ENHANCE
Research Team
J
Jared Robinson
S
Susan Zhao
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here